Roche has failed to prove the effectiveness of atropisomers in the treatment of ulcerative colitis

Roche received inconclusive test results, medication against ulcerative colitis atropisomers (etrolizumab) in patients with moderately severe and severe form of the disease. About it writes Reuters.

The company explained that in both studies, the effect of atropisomers as a maintenance therapy. As evidenced by the obtained data, the drug use has no statistically significant effectiveness in terms of achievement of remission compared to placebo.

Despite the setback for this indication Roche intends to continue research atropisomers among patients with Crohn’s disease.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]